Well Lead Medical (Well Lead) in China has awarded a new contract to Bactiguard, a Sweden-based meditech company.
It was reported on Friday that the order is to generate revenues of around SEK16.5m in the fourth quarter of 2019.
Christian Kinch, CEO, stated: "This is the second order from Well Lead outside the initial contract and further strengthens that end-customer sales in China are picking up. At the same, we don't expect to receive any new orders from Well Lead in the beginning of next year, given the high volumes delivered in the third and fourth quarters of this year."
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
Everest Medicines expands I-MAB investment
Perrigo Announces Quarterly Dividend
Ridgetech reports net income of USD10.20m in fiscal year 2025
Sanofi finalizes acquisition of Blueprint Medicines to expand rare disease and immunology portfolio
Perrigo to divest Dermacosmetics business for up to EUR327m
CVS Health declares quarterly dividend USD0.665 per share
Lilly declares dividend of USD1.50 for Q3
Bavarian Nordic sells US Priority Review Voucher for USD160m